Anti-cancer Mechanism of Docosahexaenoic Acid in Pancreatic Carcinogenesis: A Mini-review

Article information

J Cancer Prev. 2017;22(1):1-5
Publication date ( electronic ) : 2017 March 30
doi : https://doi.org/10.15430/JCP.2017.22.1.1
Brian Korea 21 PLUS Project, Department of Food and Nutrition, College of Human Ecology, Yonsei University, Seoul, Korea
Correspondence to: Hyeyoung Kim, Department of Food and Nutrition, College of Human Ecology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea, Tel: +82-2-2123-3125, Fax: +82-2-364-5781, E-mail: kim626@yonsei.ac.kr, ORCID: Hyeyoung Kim, http://orcid.org/0000-0002-7019-917X
received : 2016 December 19, accepted : 2017 January 23.

Abstract

Pancreatic cancer is a highly aggressive malignant tumor of the digestive system and radical resection, which is available to very few patients, might be the only possibility for cure. Since therapeutic choices are limited at the advanced stage, prevention is more important for reducing incidence in high-risk individuals with family history of pancreatic cancer. Epidemiological studies have shown that a high consumption of fish oil or ω3-polyunsaturated fatty acids reduces the risk of pancreatic cancers. Dietary fish oil supplementation has shown to suppress pancreatic cancer development in animal models. Previous experimental studies revealed that several hallmarks of cancer involved in the pathogenesis of pancreatic cancer, such as the resistance to apoptosis, hyper-proliferation with abnormal Wnt/β-catenin signaling, expression of pro-angiogenic growth factors, and invasion. Docosahexaenoic acid (DHA) is a ω3-polyunsaturated fatty acid and rich in cold oceanic fish oil. DHA shows anti-cancer activity by inducing oxidative stress and apoptosis, inhibiting Wnt/β-catenin signaling, and decreasing extracellular matrix degradation and expression of pro-angiogenic factors in pancreatic cancer cells. This review will summarize anti-cancer mechanism of DHA in pancreatic carcinogenesis based on the recent studies.

INTRODUCTION

Pancreatic cancer remains difficult to treat, despite the recent advances in various anti-cancer therapies. Because of difficulties in early diagnosis, most patients with pancreatic cancer receive chemotherapy and/or surgical treatment.1 Therefore, prevention and early diagnosis are important for reducing incidence of pancreatic cancer.

In recent Japanese cohort study, there was an inverse relationship between the risk of pancreatic cancer and ω3-polyunsaturated fatty acids (PUFAs) consumption.2 Macášek et al.3 studied plasma fatty acid composition in patients with pancreatic cancer. They found that longer-term survival of pancreatic cancer patients was connected with higher consumption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The proportions of EPA and DHA in plasma phospholipid displayed negative trend with tumor staging.3 He et al.4 conducted a prospective cohort study for associations of fish types and fish preparation methods with pancreatic cancer risk in Washington State. They found that DHA showed a greater inverse association with pancreatic cancer than EPA. Mohammed et al.5 determined the impact of w3-PUFAs on pancreatic intraepithelial neoplasms (PanINs) and their progression to pancreatic ductal adenocarcinoma (PDAC) using ω3-fatty acid desaturase (Fat-1) transgenic mice, which can convert ω6-PUFA to ω3-ftty acids endogenously. They found a dramatic reduction in incidence of PDAC in compound Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice compared to p48(Cre/+)-LSL-Kras(G12D/+) mice. In addition, significant reductions of pancreatic ducts with carcinoma and PanIN 3 lesions were observed in the compound transgenic mice. The levels of ω3-PUFAs were much higher in pancreas of compound transgenic mice than in those of p48(Cre/+)-LSL-Kras(G12D/+) mice. Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice showed lower levels of proliferating cell nuclear antigen, COX-2, 5-lipoxygenase (5-LOX), 5-LOX-activating protein, Bcl-2, and cyclin D1 than p48(Cre/+)-LSL-Kras(G12D/+) mice.5 These studies suggest that dietary ω3-PUFAs may prevent development of pancreatic cancer in high-risk individuals. In addition, DHA undergoes rapid uptake into cells which is sustained for the length of the treatment course. Therefore, this regimen is appropriate for therapies for cancer patients.6 Even though DHA is a promising therapeutic agent for pancreatic cancer, there has been relatively little studies to explain how DHA supplementation inhibits the development of pancreatic cancer.

Pancreatic carcinogenesis involves the resistance to apoptosis,7,8 hyper-proliferation with abnormal Wnt/β-catenin signaling,9,10 invasion,11 and expression of pro-angiogenic growth factors.12 DHA, one of ω3-PUFAs, exhibits good anti-inflammatory and anti-neoplastic properties by inducing oxidative stress,13 inhibiting β-catenin accumulation,14 and suppressing degradation of extracellular cellular matrix proteins15 and expression of growth factors16,17 in pancreatic cancer cells. Here, we review the anti-cancer mechanisms of DHA in pancreatic carcinogenesis based on the recent studies.

PATHOLOGIC MECHANISM OF PANCREATIC CARCINOGENESIS

Pancreatic cancer cells show resistance to apoptosis in several levels of apoptotic pathways.18,19 Pancreatic cancer cells have been reported to produce non-functional death signal receptors,20 overexpress Bcl-family proteins,7 or block caspase activation.8 These kinds of apoptosis evasion make the cancer cells become tolerant to cancer therapies, and promote cancer progression.8 Recent study showed that the primary pancreatic cancers expressed toll-like receptor (TLR) –2, –4, and –9. TLR-specific stimulation resulted in the activation of mitogen-activated protein kinase signaling and expression of VEGF and platelet-derived growth factor (PDGF). Moreover, TLR activation prompted the expression of Bcl-xL to induce tumor cell proliferation in pancreatic cancer.21 TGF-β has a dual role in tumorigenesis, acting as a tumor suppressor in normal cells and in the early stages of tumor development while promoting carcinogenesis and metastasis in advanced tumor stages.22 Witte et al.22 reported that proteinase-activated receptor 2 (PAR2) is a novel regulator of TGF-β signaling in pancreatic cancer. Since PAR2 controls the expression of TGF-β type I receptor, anaplastic lymphoma kinase (ALK)5, PAR2 may also impact signaling by other TGF-β superfamily members that signal through ALK5. Thus, PAR2 could represent a molecular linker between pancreatic cancer development and cancer-related cachexia.

Dysregulation of Wnt/β-catenin signaling is found in many types of cancers, including pancreatic cancer.9,10 During embryotic development and tissue homeostasis, Wnt/β-catenin signaling regulates fundamental processes, such as proliferation, polarity, and fate determination of cells.23 When Wnt signal is absent, the scaffolding protein Axin recruits glycogen synthase kinase-3 (GSK3), casein kinse 1α (CK1α), adenomatous polyposis coli gene product, and β-catenin, forming a destruction complex. CK1α and GSK3 are kinase proteins which phosphorylate serine 45 and threonine 41, serine 33, and serine 37 of β-catenin, respectively.23 This phosphorylated β-catenin serves as a binding site for the E3 ubiquitin ligase, β-transducin repeat-containing protein. Ubiquitination of β-catenin results in proteasome degradation. However, when Wnt binds to frizzled receptors, the axin complex loses its destruction activity, leading to accumulation of β-catenin in cytoplasm. High concentration of β-catenin in cytoplasm eventually causes its nuclear translocation.24 In nucleus, β-catenin acts as a transcription cofactor for genes related to cell proliferation, migration, and matrix metallo-proteases secretion.10 Constitutively active Wnt/β-catenin signaling is a feature of pancreatic cancer.9

One of the reasons why survival rate of pancreatic cancer is so low is due to a high risk of local invasion and metastasis in pancreatic cancer. The incidence of lymphatic metastasis in pancreatic cancer is about 65.3% to 89.0%.11 Metastasization begins with invasion of tumor cells into surrounding tissue. Tumor cells release hydrolytic enzymes such as matrix metallo-proteases and disintegrate extracellular matrix (ECM), then migrate to blood or lymphatic vessels.25 Rapidly growing cancer cells need more blood vessels in order to meet their metabolic requirements. Thus, tumor growth is dependent on angiogenesis. There are several cytokines and growth factors stimulating or inhibiting angiogenesis. VEGF is one of the most studied angiogenic growth factor. VEGF has been reported to increase vascular permeability, stimulate endothelial cell proliferation and migration, and promote endothelial cell survival.26 In addition, VEGF and its receptor are up-regulated in pancreatic cancer cells.12

EFFECT OF DOCOSAHEXAENOIC ACID ON PANCREATIC CARCINOGENESIS

In 1998, Hawkins et al.27 reported that apoptotic death of human Mia-PaCa-2 pancreatic cancer cells induced by PUFAs varies with double bond number and involves an oxidative mechanism. They found correlations between the number of fatty acid double bonds and the proportion of apoptotic cells. The extent of PUFAs-induced lipid peroxidation, measured as malondialdehyde, also correlated with the proportion of apoptosis. This is the first study showing the relation of oxidative stress and apoptosis in pancreatic cancer cells. Later, Merendino et al.28 reported that DHA exhibited active glutathione (GSH) extrusion and increased reactive oxygen species (ROS) which mediate apoptotic cell death of human PaCa-44 pancreatic cancer cells.7 Inhibition of GSH efflux completely reversed apoptosis of pancreatic cancer cells.7 Fukui et al.29 also showed that EPA and DHA induced ROS accumulation and caspase-8-dependent cell death in human pancreatic cancer cells. They also demonstrated that 5% fish oil supplementation reduced the growth of MIA-PaCa-2 xenografts in athymic nude mice.29 We recently summarized that oxidized DHA leads to DNA adduct formation. Oxidative DNA damage triggers cell cycle arrest and apoptosis by p53-dependent and p53-independent pathways in cancer cells.30 Zhang et al.31 reported that DHA and EPA inhibits proliferation and induce apoptosis of human SW 1990 pancreatic cancer cells by down-regulating cyclin E expression.

DHA suppressed pancreatic cancer cell growth by inhibiting activation of Wnt/β-catenin signaling.14 DHA inhibited the accumulation of β-catenin in cytoplasm and nucleus, and decreased overall β-catenin protein level in human pancreatic cancer cells, SW1990 and Panc-1.14 DHA increased the binding of GSK-3β to axin, promoting the phosphorylation and degradation of β-catenin. Activity of the transcription factor, TCF/LEF, which forms a complex with β-catenin in nucleus, was suppressed by DHA in a dose-dependent manner.

DHA inhibited COX-2 expression and prostaglandin E2 production which mediates cancer cell invasion.32 Therefore, DHA was suggested as a potential adjuvant in the treatment of cancer. According to D’Eliseo et al.,33 DHA inhibited invasion of PT45 pancreatic carcinoma cells by down-modulation of granzyme B expression. Granzyme B is a serine protease which is expressed by cytotoxic lymphocytes to induce target cell apoptosis. However, granzyme B is also produced by a variety of normal and neoplastic cells and potentially acts on multiple targets. Granzyme B is considered as a powerful regulator of a wide range of fundamental biological processes. Tumor-expressed granzyme B degrades ECM components and promotes cancer cell invasion.9 This study is supported by Strouch et al.34 who showed that a high ω3-fatty acid diet mitigates murine pancreatic precancer development.

Recent study showed that ω3-PUFAs supplementation reduced circulating pro-angiogenic growth factors, such as PDGF, in the patients with advanced pancreatic cancer.17 Spencer et al.26 suggested that DHA and EPA have potent anti-angiogenic effects by inhibiting production of many important angiogenic mediators namely; VEGF, PDGF, platelet-derived endothelial cell growth factor, COX-2, prostaglandin E2, nitric oxide, NF-κB, matrix metalloproteinases, and β-catenin. They showed that DHA and EPA have therapeutic potential to inhibit tumor angiogenesis in colon, breast, and prostate cancers. However, there has been little research on the effect of DHA on angiogenesis specifically in pancreatic cancer cells. Therefore, it is important to determine whether DHA has an inhibitory effect on angiogenesis in pancreatic cancer cells, which provide insights into the molecular mechanisms by which dietary DHA suppresses the progression of pancreatic cancer.

Swamy et al.35 found that a synergistic effect was observed on induction of apoptosis (approximately six-fold) and inhibition of cell proliferation (approximately 70%) when pancreatic cancer (BxPC-3) cells were treated with curcumin together with the DHA. A combination of fish oil and curcumin showed a significantly reduced tumor volume in mice. Expression and activity of inducible nitric oxide synthase, COX-2, and 5-LOX are down-regulated, and p21 is upregulated in tumor xenograft fed cur-cumin combined with fish oil diet when compared to individual diets. Therefore, the combined natural products, such as curcumin and ω3-fatty acids, may provide synergistic pancreatic tumor inhibitory properties.

Previously, we showed that janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway stimulates cell proliferation and malignant transformation and inhibits apoptosis in pancreas.36,37 Since DHA reduced STAT3 activation in human liver cancer (HepG2) cells38 and gastric cancer (AGS) cells,39 DHA may inhibit JAK/STAT pathway in pancreatic cancer cells. Further study should be performed to determine the effect of DHA on JAK/STAT in pancreatic carcinogenesis. Because the incidence of and mortality from pancreatic cancer is rising, further study of new approaches for prevention of pancreatic cancer using DHA is essential.

CONCLUSION

DHA induces apoptosis through ROS accumulation and caspase activation in pancreatic cancer cells. It also down-regulates Wnt/β-catenin signaling that stays activated in pancreatic cancer cells. Moreover, DHA suppresses expression of pro-angiogenic growth factors, such as VEGF and PDGF, preventing cancer cells from getting metabolic requirements and proliferating. Furthermore, granzyme B is down-regulated by DHA. Conclusively, supplementation of DHA-rich foods may prevent the development of pancreatic cancers. Further long-term clinical studies are necessary to determine the preventive effect of DHA against pancreatic cancer development (Fig. 1).

Figure 1

The preventive effect of docosahexaenoic acid (DHA) against pancreatic cancer development. In pancreatic cancer cells, DHA induces glutathione (GSH) extrusion which increases the levels of reactive oxygen species (ROS) and caspase activation, resulting in ROS-mediated apoptosis. DHA also inhibits activation of Wnt/β-catenin signaling by increasing binding of glycogen synthase kinase-3β (GSK3β) to axin and reducing β-catenin accumulation as well as expression of cyclin E. Thus, DHA suppresses cancer cell proliferation. DHA down-regulates gran-zyme B, which degrades extracellular matrix (ECM) and promotes cancer cell invasion. DHA also reduces pro-angiogenic factors, such as VEGF and platelet-derived growth factor (PDGF). Therefore, DHA may inhibit resistance to cancer therapies and cancer development, and increase survival rate of pancreatic cancer patients.

ACKNOWLEDGMENTS

This work was supported by a grant from the NRF of Korea, which is funded by the Korean government (NRF-2015R1A2A 2A01004855).

Notes

CONFLICTS OF INTEREST

No potential conflicts of interest were disclosed.

References

1. Zhang Q, Chen S, Zeng L, Chen Y, Lian G, Qian C, et al. New developments in the early diagnosis of pancreatic cancer. Expert Rev Gastroenterol Hepatol 2017;11:149–56.
2. Hidaka A, Shimazu T, Sawada N, Yamaji T, Iwasaki M, Sasazuki S, et al. Fish, n-3 PUFA consumption, and pancreatic cancer risk in Japanese: a large, population-based, prospective cohort study. Am J Clin Nutr 2015;102:1490–7.
3. Macášek J, Vecka M, Žák A, Urbánek M, Krechler T, Petruželka L, et al. Plasma fatty acid composition in patients with pancreatic cancer: correlations to clinical parameters. Nutr Cancer 2012;64:946–55.
4. He K, Xun P, Brasky TM, Gammon MD, Stevens J, White E. Types of fish consumed and fish preparation methods in relation to pancreatic cancer incidence: the VITAL Cohort Study. Am J Epidemiol 2013;177:152–60.
5. Mohammed A, Janakiram NB, Brewer M, Duff A, Lightfoot S, Brush RS, et al. Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1- p48(Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia 2012;14:1249–59.
6. Arshad A, Chung WY, Isherwood J, Mann CD, Al-Leswas D, Steward WP, et al. Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancer. Clin Nutr 2014;33:895–9.
7. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008;7:64
8. Müerköster SS, Lust J, Arlt A, Häsler R, Witt M, Sebens T, et al. Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene 2006;25:3973–81.
9. Sarkar S, Mandal C, Sangwan R, Mandal C. Coupling G2/M arrest to the Wnt/β-catenin pathway restrains pancreatic adenocarcinoma. Endocr Relat Cancer 2014;21:113–25.
10. Jamieson C, Sharma M, Henderson BR. Targeting the β-catenin nuclear transport pathway in cancer. Semin Cancer Biol 2014;27:20–9.
11. Hosch SB, Knoefel WT, Metz S, Stoecklein N, Niendorf A, Broelsch CE, et al. Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance. Pancreas 1997;15:154–9.
12. Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, et al. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 2011;11:286
13. Merendino N, Molinari R, Loppi B, Pessina G, D’ Aquino M, Tomassi G, et al. Induction of apoptosis in human pancreatic cancer cells by docosahexaenoic acid. Ann N Y Acad Sci 2003;1010:361–4.
14. Song KS, Jing K, Kim JS, Yun EJ, Shin S, Seo KS, et al. Omega-3-polyunsaturated fatty acids suppress pancreatic cancer cell growth in vitro and in vivo via downregulation of Wnt/Beta-catenin signaling. Pancreatology 2011;11:574–84.
15. D’Eliseo D, Pisu P, Romano C, Tubaro A, De Nunzio C, Morrone S, et al. Granzyme B is expressed in urothelial carcinoma and promotes cancer cell invasion. Int J Cancer 2010;127:1283–94.
16. Zhuang W, Wang G, Li L, Lin G, Deng Z. Omega-3 polyunsaturated fatty acids reduce vascular endothelial growth factor production and suppress endothelial wound repair. J Cardiovasc Transl Res 2013;6:287–93.
17. Arshad A, Chung WY, Steward W, Metcalfe MS, Dennison AR. Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB (Oxford) 2013;15:428–32.
18. Arlt A, Müerköster SS, Schäfer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett 2013;332:346–58.
19. Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med 2009;13:1221–7.
20. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999;125:73–84.
21. Grimmig T, Moench R, Kreckel J, Haack S, Rueckert F, Rehder R, et al. Toll like receptor 2, 4, and 9 signaling promotes autoregulative tumor cell growth and VEGF/PDGF expression in human pancreatic cancer. Int J Mol Sci 2016;17:2060
22. Witte D, Zeeh F, Gädeken T, Gieseler F, Rauch BH, Settmacher U, et al. Proteinase-activated receptor 2 is a novel regulator of TGF-β signaling in pancreatic cancer. J Clin Med 2016;5:111
23. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9–26.
24. Wu MY, Xie X, Xu ZK, Xie L, Chen Z, Shou LM, et al. PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/β-catenin pathway by phosphorylation and degradation of β-catenin. Oncol Rep 2014;32:513–22.
25. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541–73.
26. Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, et al. The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur J Cancer 2009;45:2077–86.
27. Hawkins RA, Sangster K, Arends MJ. Apoptotic death of pancreatic cancer cells induced by polyunsaturated fatty acids varies with double bond number and involves an oxidative mechanism. J Pathol 1998;185:61–70.
28. Merendino N, Loppi B, D’Aquino M, Molinari R, Pessina G, Romano C, et al. Docosahexaenoic acid induces apoptosis in the human PaCa-44 pancreatic cancer cell line by active reduced glutathione extrusion and lipid peroxidation. Nutr Cancer 2005;52:225–33.
29. Fukui M, Kang KS, Okada K, Zhu BT. EPA, an omega-3 fatty acid, induces apoptosis in human pancreatic cancer cells: role of ROS accumulation, caspase-8 activation, and autophagy induction. J Cell Biochem 2013;114:192–203.
30. Song EA, Kim H. Docosahexaenoic acid induces oxidative DNA damage and apoptosis, and enhances the chemosensitivity of cancer cells. Int J Mol Sci 2016;17:1257
31. Zhang W, Long Y, Zhang J, Wang C. Modulatory effects of EPA and DHA on proliferation and apoptosis of pancreatic cancer cells. J Huazhong Univ Sci Technolog Med Sci 2007;27:547–50.
32. Merendino N, Costantini L, Manzi L, Molinari R, D’Eliseo D, Velotti F. Dietary ω-3 polyunsaturated fatty acid DHA: a potential adjuvant in the treatment of cancer. Biomed Res Int 2013;2013:310186
33. D’Eliseo D, Manzi L, Merendino N, Velotti F. Docosahexaenoic acid inhibits invasion of human RT112 urinary bladder and PT45 pancreatic carcinoma cells via down-modulation of granzyme B expression. J Nutr Biochem 2012;23:452–7.
34. Strouch MJ, Ding Y, Salabat MR, Melstrom LG, Adrian K, Quinn C, et al. A high omega-3 fatty acid diet mitigates murine pancreatic precancer development. J Surg Res 2011;165:75–81.
35. Swamy MV, Citineni B, Patlolla JM, Mohammed A, Zhang Y, Rao CV. Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr Cancer 2008;60(Suppl 1):81–9.
36. Yu JH, Kim H. Role of janus kinase/signal transducers and activators of transcription in the pathogenesis of pancreatitis and pancreatic cancer. Gut Liver 2012;6:417–22.
37. Yu JH, Kim H. Oxidative stress and cytokines in the pathogenesis of pancreatic cancer. J Cancer Prev 2014;19:97–102.
38. Wang TM, Hsieh SC, Chen JW, Chiang AN. Docosahexaenoic acid and eicosapentaenoic acid reduce C-reactive protein expression and STAT3 activation in IL-6-treated HepG2 cells. Mol Cell Biochem 2013;377:97–106.
39. Ji HG, Piao JY, Kim SJ, Kim DH, Lee HN, Na HK, et al. Docosahexaenoic acid inhibits Helicobacter pylori-induced STAT3 phosphorylation through activation of PPARγ. Mol Nutr Food Res 2016;60:1448–57.

Article information Continued

Figure 1

The preventive effect of docosahexaenoic acid (DHA) against pancreatic cancer development. In pancreatic cancer cells, DHA induces glutathione (GSH) extrusion which increases the levels of reactive oxygen species (ROS) and caspase activation, resulting in ROS-mediated apoptosis. DHA also inhibits activation of Wnt/β-catenin signaling by increasing binding of glycogen synthase kinase-3β (GSK3β) to axin and reducing β-catenin accumulation as well as expression of cyclin E. Thus, DHA suppresses cancer cell proliferation. DHA down-regulates gran-zyme B, which degrades extracellular matrix (ECM) and promotes cancer cell invasion. DHA also reduces pro-angiogenic factors, such as VEGF and platelet-derived growth factor (PDGF). Therefore, DHA may inhibit resistance to cancer therapies and cancer development, and increase survival rate of pancreatic cancer patients.